<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00524394</url>
  </required_header>
  <id_info>
    <org_study_id>HSC-MS-07-0021</org_study_id>
    <nct_id>NCT00524394</nct_id>
  </id_info>
  <brief_title>Characteristics of Cord Blood Immunologic Parameters of Infants &lt;32 Weeks Gestation</brief_title>
  <acronym>AOS</acronym>
  <official_title>Characteristics of Cord Blood Immunologic Parameters of Infants &lt; 32 Weeks Gestation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Infants in the NICU are at high risk for morbidity and mortality from infections of any
      onset. Diagnosis of these infections is imperfect at best. Patterns of inflammatory and
      regulatory proteins (cytokines &amp; chemokines, in addition to antigen detection on antibody
      secreting cells (ASC's)may provide a more accurate and rapid approach to diagnosis of
      infections in these high-risk patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sampling methods/Data collection

      Samples: Serum (1-2ml) from enrolled infants will be collected from cord blood (T0). Serial
      samples (0.5-1ml) will be collected at 3 other times: T1= 4-7 days, T2=10-14 days, T3= 20-30
      days. These can be drawn at initiation of any sepsis work-up, or prior to any transfusion of
      PRBC's or when any blood ≥0.5ml will be wasted. These collections are intended to analyze the
      immunologic milieu in infants at various stages of natal and post-natal immune adaptation:

        1. baseline levels from a relatively privileged environment (cord blood T0)

        2. peak of immunogenic response after prenatal exposure (T1)

        3. plateau of immunogenic response after perinatal exposure (T2)

        4. relative state of equilibrium with surrounding flora (T3)

      Data collection:

      Baseline statistics at enrollment: Birth weight, obstetrical assessment of gestational age,
      mode of delivery, presence of labor, presence of IAI, ROM, intrapartum antibiotics type and
      length, With each sampling, data will be gathered via chart review on each infant. We will
      also gather data at 60 DOL, discharge, or death on any infant enrolled.

      Measurements:

      Experimental laboratory:

      Cytokines- Each sample will have plasma analyzed by Luminex (Biorad) to determine profiles of
      cytokines: IL-2, IL-6, IL-8, IL-13, MIP1b, MCP1, IL-1b, IL-4, IL-5, IL-7, IL-10, IL-12p70,
      IL-17, GMCSF, IFN-gamma, and TNF-alpha. Standard curves for each cytokine measurement were
      run to determine upper and lower limits of detection.

      ASC- will be quantified by enzyme-linked immunospot assay (ELISPOT) for specific isotypes
      IgA, IgM, and IgG. They will also be linked to 3 particular immunogenic agents: GBS, Candida,
      and CoNS.

      Clinical laboratory:

      Total WBC and band ratio will be run in the routine course of care for these infants. This is
      not an additional sample.

      serious bacterial infections other than sepsis (meningitis, UTI)

        -  Course of Study- 0-30 days of life for sampling. 0-60 days of life for data collection.

        -  Enrollment- consecutive admissions of NICU under the following criteria

      Inclusion:

      Admitted to NICU at MHCH

        -  1500gm or ≤ 32 wk GA Birth to &lt;31 days of life at time of enrollment

      Exclusion:

      Known or suspected immunodeficiency (including maternal HIV or other known congenital
      infection) Known major congenital anomaly

        -  Recruitment Will include each eligible infant by the primary investigator or
           co-investigators. Assuming an incidence of LOS of ~25% and EOS of ~1-3%, a power of 80%,
           we should enroll 50 infants. This coincides with prior studies evaluating ASC's response
           in neonates, and those evaluating cytokines in cord blood and post-natally.

        -  Known Risks There will be no additional blood draws. There will be collection of a
           greater volume of blood (additional 0.5ml-1.0ml depending on size of infant) during
           clinical indications for blood draws. No clinical decisions will be made based on the
           data obtained.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    recruitment not possible
  </why_stopped>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Immunological Homeostasis</measure>
    <time_frame>0 to 30 days of life.</time_frame>
    <description>Describe changes in immunological homeostasis that indicate the &quot;normal&quot; function vs. presence of sepsis in newborn infants of various gestational ages</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cytokines</measure>
    <time_frame>O TO 30 DAYS OF LIFE</time_frame>
    <description>IL2 IL6 IL8 IL13 MIP1B MCP1 IL1B IL4 IL5 IL7 IL10 IL12P70 Measure of Cytokines presence and level .</description>
  </primary_outcome>
  <enrollment type="Actual">2</enrollment>
  <condition>Premature Birth</condition>
  <condition>Sepsis</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum only
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Premature infants
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Infants born at Children's Memorial Hermann Hospital with cord blood available &lt;
             1500gm or &lt; 32 weeks gestation by OB estimate

        Exclusion Criteria:

          -  Outborn infants transferred to CMHH without cord blood available

          -  Parents to not consent

          -  &gt; 1500gm or &gt; 32 weeks gestation by OB estimate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>3 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James R Murphy, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas at Houston</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Memorial Hermann Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 30, 2007</study_first_submitted>
  <study_first_submitted_qc>August 31, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 3, 2007</study_first_posted>
  <results_first_submitted>July 17, 2013</results_first_submitted>
  <results_first_submitted_qc>November 5, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 14, 2015</results_first_posted>
  <last_update_submitted>November 5, 2015</last_update_submitted>
  <last_update_submitted_qc>November 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>VLBW</keyword>
  <keyword>sepsis</keyword>
  <keyword>diagnosis</keyword>
  <keyword>suspected sepsis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Premature Birth</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment using NICU ADMISSION LIST.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Infants 0 to 3 Days of Life &gt;1500 g or &gt;32 Weeks GA</title>
          <description>Infants born at &gt;32 weeks of gestagional age or &gt; 1500gm between 0 to 3 Days of Life</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>INFANTS</title>
          <description>INFANTS 0 to 3 days of life &gt;1500 G OR &gt;32 WEEKS GA</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Immunological Homeostasis</title>
        <description>Describe changes in immunological homeostasis that indicate the &quot;normal&quot; function vs. presence of sepsis in newborn infants of various gestational ages</description>
        <time_frame>0 to 30 days of life.</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cytokines</title>
        <description>IL2 IL6 IL8 IL13 MIP1B MCP1 IL1B IL4 IL5 IL7 IL10 IL12P70 Measure of Cytokines presence and level .</description>
        <time_frame>O TO 30 DAYS OF LIFE</time_frame>
        <population>zero participant analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>INFANTS 0 to 3 Days of Life (DOL) &gt;1500 G OR &gt;32 WEEKS GA</title>
            <description>INFANTS 0 to 3 days of life born with &gt;1500 gm OR &gt;32 WEEKS gestational age</description>
          </group>
        </group_list>
        <measure>
          <title>Cytokines</title>
          <description>IL2 IL6 IL8 IL13 MIP1B MCP1 IL1B IL4 IL5 IL7 IL10 IL12P70 Measure of Cytokines presence and level .</description>
          <population>zero participant analyzed</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From begining to the end of the study period.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Infants0-3 Days of Life &gt;1500g or &gt;32 Weeks GA</title>
          <description>Infants born at 32 weeks of gestacional age or &gt;1500 mg at 0-3 days of life .</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination leading to small numbers of subjects analyzed</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>James Murphy, PhD</name_or_title>
      <organization>University of Texas Health Science Center</organization>
      <phone>713-500-5714</phone>
      <email>james.r.murphy@uth.tmc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

